Tumor cells tend to evade CTL destruction by upregulating immune checkpoint ligands (e.g., PD-L1) that can bind to complementary receptors (PD-1) on CTLs, leading to the suppression of lymphocyte activation. The gene discussed is PDCD1; the disease is neoplasm.